Skip to main content
. Author manuscript; available in PMC: 2012 Jun 14.
Published in final edited form as: Cancer. 2010 Dec 14;117(11):10.1002/cncr.25719. doi: 10.1002/cncr.25719

Table 4.

Patient and disease characteristics for risk stratification using traditional prognostic factors in RMS. Risk stratification groups are defined in Table 3.

Low Risk (n=141) Medium Risk (n=166) High Risk (n=63) p-value* (overall test)
Count (%) Count (%) Count (%)
Age (years) ----------
 <1 5 ( 4%) 5 ( 3%)
 1–9 109 (77%) 146 (88%)
 10+ 27 (19%) 15 ( 9%) 63 (100%)
Stage <0.001
 1 24 (17%) 8 ( 5%) 3 ( 5%)
 2 70 (50%) 28 (17%) 6 (10%)
 3 47 (33%) 130 (78%) 54 (86%)
Group 0.3
 I 7 ( 5%) 4 ( 2%) 1 ( 2%)
 II 16 (11%) 11 ( 7%) 5 ( 8%)
 III 118 (84%) 151 (91%) 57 (90%)
Primary Site ----------
 Extremity 26 (18%) 29 (17%) 13 (21%)
 GU/BP 56 (40%) 6 (10%)
 Parameningeal 28 (20%) 78 (47%) 34 (54%)
 Retroperitoneal/Perineal 1 ( 1%) 44 (27%) 4 ( 6%)
 Other 30 (21%) 15 ( 9%) 6 (10%)
Tumor Size ----------
 ≤ 5 cm 103 (73%) 34 (20%) 9 (14%)
 >5 cm 38 (27%) 132 (80%) 54 (86%)
Tumor Invasion <0.001
 T-1 85 (60%) 65 (39%) 22 (35%)
 T-2 56 (40%) 101 (61%) 41 (65%)
Regional Lymph Nodes <0.001
 N-0 125 (89%) 142 (86%) 42 (67%)
 N-1 16 (11%) 24 (14%) 21 (33%)
Histology <0.001
 Embryonal 70 (50%) 100 (60%) 13 (21%)
 Alveolar 59 (42%) 58 (35%) 42 (67%)
 Undifferentiated 0 5 ( 3%) 3 ( 5%)
 RMS, NOS 12 ( 9%) 3 ( 2%) 5 ( 8%)
Strata <0.001
 Embryonal Stage 2/3 Group III 70 (50%) 74 (45%) 13 (21%)
 ALV/UDS Stage 1 or Group I 27 (19%) 11 ( 7%) 3 ( 5%)
 ALV/UDS other 34 (24%) 42 (25%) 32 (51%)
 PM with extension 10 ( 7%) 39 (23%) 15 (24%)
*

Distributions were compared among groups using a Chi-square test or Fisher’s exact test. No formal comparison was made for factors involving age, maximum diameter, and primary site, which were used directly in the risk group definitions.